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this model is called “structure-process-outcome”. The Kozma model, place outcomes into three 
categories - economic, clinical, and humanistic Outcomes (ECHO model) which characterize 
the value of pharmaceutical services. According to risk model, risks are analyzed by combining 
severity of consequences and probability in the context of existing situation, in PI are evaluated 
medication errors. According to the basic model of pharmacoeconomics, the value of a PI 
considers both inputs and outputs of a PI compared to the absence of a PI. Inputs can be thought 
of as resources required implementing the PI. Outputs can be thought of as consequences of a 
PI, in form of clinical, humanistic, or process-related consequences. The difference between 
the cost of the original therapy and the new therapy gives the cost savings (or the increase in 
the cost of therapy). Cost avoidance refers to the prevention of additional health resources 
which are required to treat drug adverse events if a pharmacist has not intervened such as a 
hospitalization or a medical visit. Cost of implementation of a PI refers to the expenses of 
providing the PI such as cost of pharmacist’s time, phone calls.   
Conclusions. Various structures and contents of tools for evaluation of impacts of PIs were 
highlighted. Majority of tools focused primarily on assessing clinical aspect and failed to detect 
other impacts.  
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Introduction. Competition reflects a relationship of forces between the economic agents in the 
market of consumer goods and targeted services for the purpose of attracting the consumer, 
resulting in growth, diversifying and improving the quality of the offer and an increase in 
consumers' demand for goods consummation, being better informed about the existing 
consummation alternatives. The pharmaceutical market has some particularities: a) a large 
number of products with very strict demands on their characteristics, a long period of research 
and a large volume of resources needed for their conditioning; b) consumers of the 
pharmaceutical market are the health system and the sick people, usually economically 
disadvantaged. In order for the effects of competition to be predominantly beneficial, it is 
necessary to regulate it, thus ensuring a balance between the interests of businesses, drug users, 
increasing the number of products offered on the market and ensuring the performances that 
characterize them (harmlessness, effectiveness, quality and accessibility).  
Aim of the study. Highlighting the regulations on the pharmaceutical market of the Republic 
of Moldova and their consequences on competition.  
Materials and methods. The study is based on an analysis of the legal norms for regulating 
some activities related to the pharmaceutical activity and substantiating these rules in terms of 
the effects on competition as an element of the market.  
Results. The pharmaceutical legislation of the Republic of Moldova contains several 
regulations that influence the level of competition in the pharmaceutical market.  1. Expansion 
and placement regulations of pharmacies. These regulations contradict the requirements of the 
market economy, examined from the point of view of the drug trade, but they were introduced 
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to ensure the interests of the consumer, to discourage excessive drug use and encourage their 
rational use, for economic agents to ensure minimum operating conditions and stimulate 
competition on the basis of ethical principles of drug assistance.  2. Data protection and 
protection of the introduction of pharmaceutical products. Data exclusivity is a form of 
intellectual property protection and allows pharmaceutical companies to use only their own 
clinical trial data for a predetermined period, as a measure of return on initial investments which 
led to the discovery of an innovative pharmaceutical preparation and the stimulation of new 
investments in this field. However, this measure conflicts with the declared priority of the 
authorities of the Republic of Moldova regarding the increase of prices for pharmaceutical 
preparations and the reduction of the financial burden related to the costs of medicines for 
citizens. Therefore, this regulation will contribute to the elimination of economic agents, 
producers of generic drugs, from the pharmaceutical market.  
Conclusions. Competitive legislative regulations of the pharmaceutical market do not always 
reflect the provisions of the state policy in the field of medicine.  
Key words: pharmaceutical market, competition, pharmacy placement, drug authorization, 
regulations.  
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Introduction.  The genus Actinidia includes about 40-60 species. During the last 2 decades, 
the scientific community has realized a lot of scientific researches on chemical composition of 
different organs, especially on species A. kolomitka. 
Materials and methods.  The profile literature and databases on species A. kolomitca were 
evaluated and analized. 
Results. Species A. kolomitka is a very long-lived, deciduous woody scrambling vine and 
creeper, which ultimately grows to 8–10 m, commonly known as variegated-leaf hardy kiwi 
which was mentionated as native to temperate mixed forests of the Russian Far East, Korea, 
Japan and China (Eastern Asiatic Region). At the beginning of XX century, this species was 
cultivated in England and North America as ornamental plant. Later, at the middle of century, 
the species began to be known as edible fruit producer, and at the end of it became the object 
of intense scientific researches. Scientific investigations were carried out under different 
aspects in different scientific centers: creation of cultivars and varieties resistant to 
environmental factors, cultivation technologies, chemical composition, nutritional and 
therapeutic value. A lot of cultivars were bread and cultivated in: Poland, Finland, Russia, 
Lithuania and Leetonia. This species was introduced in the collection of exotic plants of 
Alexandru Ciubotaru National Botanical Garden (Institute) in 1998 year. The world scientific 
researchers shown the useful chemical compounds in different organs of plant: ascorbic acid 
and other organic acids, pectins, tannins, sugars, vitamins P, Q, carotene in fruits; alkaloids – 
roots; lactones, flavonoids, saponins – leaves; and flavonoids such catechins – cork. 
